Unique technology, Unique market

Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.

Annual general meeting May 19, 2022
Link to AGM documents.

Capital Markets Day, May 24, 2022
Link to information regarding the Capital Markets Day.




  • Latest report

    Interim Report Q1 2022

  • Subscribe

    Get our latest press releases and reports

Press releases

All press releases

Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.

We see a large potential for our product portfolio. Our technology is compatible for most of the 72 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, Dasynoc. The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO

Contact us

  • Please let us know if you have any questions about the company or the product. We will get back to you as soon as we can.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.